Core Viewpoint - The company Baolingbao announced on November 5 that as of October 31, 2025, the total number of shareholders is expected to reach 33,596 [2] Summary by Categories - **Company Information** - Baolingbao has communicated with investors regarding its shareholder count, indicating a projected total of 33,596 shareholders by the end of October 2025 [2] - **Investor Communication** - The company actively engages with investors through interactive platforms, providing updates on shareholder statistics [2]

Company Overview - Baolingbao Bio-Technology Co., Ltd. is located in Dezhou, Shandong Province, and was established on October 16, 1997, with its listing date on August 28, 2009 [1] - The company's main business involves the research, production, and sales of functional sugars, with revenue composition as follows: starch sugars and others 29.89%, sugar-reducing sweeteners 26.55%, feed and by-products 22.40%, probiotics 13.48%, dietary fibers 7.39%, and others 0.29% [1] Financial Performance - For the period from January to September 2025, Baolingbao achieved operating revenue of 2.126 billion yuan, representing a year-on-year growth of 15.98%, and a net profit attributable to shareholders of 134 million yuan, reflecting a year-on-year increase of 32.58% [2] - Since its A-share listing, Baolingbao has distributed a total of 309 million yuan in dividends, with 95.072 million yuan distributed over the past three years [3] Stock Performance - As of November 4, Baolingbao's stock price decreased by 2.01% to 9.76 yuan per share, with a total market capitalization of 3.714 billion yuan [1] - Year-to-date, the stock price has increased by 33.33%, with a slight increase of 0.83% over the last five trading days, but a decline of 0.10% over the last 20 days and 9.04% over the last 60 days [1] - The company has appeared on the "Dragon and Tiger List" five times this year, with the most recent appearance on May 22, where it recorded a net buy of -50.8373 million yuan [1] Shareholder Information - As of October 20, Baolingbao had 33,700 shareholders, a decrease of 0.69% from the previous period, with an average of 10,972 circulating shares per shareholder, which is an increase of 0.70% [2]

Core Insights - The agricultural processing sector experienced a rise of 0.87% on November 3, with Huazi Industrial leading the gains [1] - The Shanghai Composite Index closed at 3976.52, up 0.55%, while the Shenzhen Component Index closed at 13404.06, up 0.19% [1] Agricultural Processing Sector Performance - Huazi Industrial (600191) closed at 9.11, up 4.35% with a trading volume of 233,300 shares and a turnover of 210 million yuan [1] - Jingliang Holdings (000505) closed at 7.02, up 3.24% with a trading volume of 253,200 shares and a turnover of 176 million yuan [1] - Zuneng Co., Ltd. (003030) closed at 21.12, up 2.92% with a trading volume of 52,800 shares and a turnover of 111 million yuan [1] - Other notable performers include COFCO Sugar (600737) at 16.01, up 2.43%, and Guangnong Sugar (000911) at 7.89, up 2.33% [1] Capital Flow Analysis - The agricultural processing sector saw a net inflow of 60.82 million yuan from institutional investors, while retail investors experienced a net outflow of 14.89 million yuan [2] - Major stocks like COFCO Sugar had a net inflow of 10.3 million yuan from institutional investors but faced significant outflows from retail investors [3] - Double Tower Food (002481) recorded a net inflow of 25.30 million yuan from institutional investors, indicating strong institutional interest [3]

Core Viewpoint - The company has obtained a drug production license for lactulose active pharmaceutical ingredient, marking a significant milestone in its strategic expansion into the raw material and health sectors [1][2]. Group 1: License Details - The drug production license was issued by the Shandong Provincial Drug Administration, with the license number Lu20250024, valid until October 28, 2030 [1]. - The production facility is located in the Yucheng High-tech Industrial Development Zone, Shandong Province, and is authorized to produce lactulose solution for registered use only [1]. Group 2: Impact on the Company - The acquisition of the drug production license accelerates the application, registration, and market launch processes for lactulose, initiating the company's diversification into raw materials [2]. - This milestone is seen as a key leverage point for enhancing industry value and strengthening market competitiveness, aligning with the company's goal to establish itself as a world-class provider of functional and health solutions [2]. - Currently, lactulose is only exported to select overseas markets, but future approvals in domestic and major global markets are expected to boost sales revenue and operational performance, although the immediate impact on current performance is anticipated to be minimal [2].

Core Viewpoint - The company has obtained a "Drug Production License" from the Shandong Provincial Drug Administration, which accelerates the application, registration, and上市 process for its first active pharmaceutical ingredient, lactulose, marking the beginning of the company's diversification in raw materials [1] Group 1 - The acquisition of the "Drug Production License" is a significant regulatory milestone for the company [1] - The license facilitates the subsequent processes for the company's first raw material drug, lactulose [1] - This development represents the start of the company's strategy to diversify its raw material offerings [1]

许可证编号：鲁 20250024 统一社会信用代码：91371400723870085E 分类码：Dh 住所(经营场所)：山东德州(禹城)高新技术产业开发区东外环路 1 号 股票代码：002286 股票简称：保龄宝 公告编号：2025-060 保龄宝生物股份有限公司 关于取得乳果糖原料药药品生产许可证的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，并对公告中的 虚假记载、误导性陈述或者重大遗漏承担责任。 近日，保龄宝生物股份有限公司(以下简称"公司""保龄宝")取得了山东 省药品监督管理局下发的《药品生产许可证》。现将相关情况公告如下： 一、《药品生产许可证》主要情况 企业名称：保龄宝生物股份有限公司 公司致力于成为世界一流的功能与健康解决方案服务商，本次保龄宝首次取 得《药品生产许可证》，是公司向原料药和大健康领域战略深化落地的核心里程 碑，更是撬动产业价值升级、夯实市场竞争力的关键支点，有利于公司树立"功 能与健康解决方案服务商"的品牌形象，实现从产品到价值的深度升级。 公司乳果糖原料药目前仅出口至部分海外国家，预计随着未来几年乳果糖原 料药在国内和全球主要国家陆续获批上市后，将增加相关产品的 ...

Core Viewpoint - The company, Baolingbao (002286.SZ), has obtained a Drug Manufacturing License from the Shandong Provincial Drug Administration, which accelerates the application, registration, and market launch process for its first active pharmaceutical ingredient, lactulose, marking the beginning of the company's diversification in raw materials [1] Group 1 - The acquisition of the Drug Manufacturing License is a significant regulatory milestone for the company [1] - The approval facilitates the subsequent steps for the company's first raw material drug, lactulose [1] - This development represents the start of the company's strategy to diversify its raw material offerings [1]

Core Viewpoint - The company, Baolingbao (002286), has recently obtained a "Drug Production License" from the Shandong Provincial Drug Administration, which allows it to produce the raw material drug lactulose solution, marking the beginning of its diversification into raw material drugs [1] Group 1 - The acquisition of the "Drug Production License" accelerates the subsequent application, registration, and market launch processes for the company's first raw material drug, lactulose [1] - This license represents a significant step in the company's strategy to diversify its raw material drug offerings [1]

Core Viewpoint - The company Baolingbao (002286.SZ) has obtained a Drug Manufacturing License from the Shandong Provincial Drug Administration, which accelerates the registration and market launch process for its first active pharmaceutical ingredient, lactulose solution [1] Group 1 - The Drug Manufacturing License was issued for the production site located at No. 1, East Outer Ring Road, Yucheng, High-tech Industrial Development Zone, Dezhou, Shandong [1] - The license specifically allows for the production of lactulose solution for registered declaration use only, marking a significant step in the company's diversification into active pharmaceutical ingredients [1] - This achievement is seen as the beginning of the company's strategy to expand its portfolio in the pharmaceutical sector [1]

Core Viewpoint - The company has obtained a Drug Manufacturing License from the Shandong Provincial Drug Administration, which accelerates the registration and market launch process for its first active pharmaceutical ingredient, lactulose solution, marking the beginning of its diversification in the active pharmaceutical ingredient sector [1] Group 1 - The Drug Manufacturing License was issued for the production site located at No. 1, East Outer Ring Road, Yucheng, High-tech Industrial Development Zone, Dezhou, Shandong [1] - The license specifically pertains to the active pharmaceutical ingredient lactulose solution, which is limited to registered declaration use [1] - The acquisition of this license is a significant step for the company in expanding its portfolio of active pharmaceutical ingredients [1]